Investment case
Elanco Animal Health Incorporated
ELAN · 2 developments mapped · last assessed 2026-09-22
Market Ontology has mapped 2 macro, policy, and market developments to Elanco Animal Health Incorporated since 2026-09-07. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ELAN yet, so no modelled value is shown. The ELAN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ELAN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0%
Peer performance and industry trends, particularly regarding global animal health market demand and currency impacts.
· Moves industry growth rate, foreign exchange rate assumptions
What changed, by assumption
- 2026-09-07Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0%
- 2026-09-22Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-22 | Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA | watch | 1-5y | 0.10 |
| 2026-09-07 | Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0% | watch | 1-3m | 0.30 |